- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05567354
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users
December 23, 2022 updated by: Ensysce Biosciences
A Randomized, Double-blind, Placebo-and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared With Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a randomized, double-blind, placebo-and active-controlled, 3-way crossover study to evaluate the abuse potential and pharmacokinetics of intranasally administered PF614, relative to crushed oxycodone HCl IR tablets and placebo in non-dependent recreational opioid users.
The study will consist of 4 phases: Screening, Qualification, Treatment, and Follow-up.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43212
- Ohio Clinical Trails
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females, aged 18 to 55 years, inclusive, in good general health.
- Body mass index (BMI) within the range of 18.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg.
- Current opioid users who have used opioids for recreational (non-therapeutic) purposes (i.e., for psychoactive effects) at least 10 times in the past year and at least once in the 12 weeks before Screening.
- Must have experience with intranasal opioids for the purpose of recreational (non-therapeutic) use on at least 3 occasions in the year prior to Screening.
- Must not be physically dependent on opioids, as demonstrated by successful completion of the Naloxone Challenge Test.
- Must meet Drug Discrimination Test eligibility criteria (Section 8.3).
- Female subjects must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at randomization. Post-menopausal women (i.e., no menstrual period for at least one year) must have a follicle-stimulation hormone (FSH) level >30 milli-international unit (mIU)/mL at Screening.
- Female subjects must use a medically acceptable method of birth control (oral or transdermal contraceptives, condom, spermicidal foam, intrauterine device (IUD), progestin implant or injection, heterosexual abstinence, vaginal ring or sterilization of partner) from the time of Screening through 2 weeks after the last study treatment.
- Male subjects must agree to use medically acceptable methods of contraception (diaphragm/sponge/condom with spermicide, vasectomy), and/or their female sexual partners of childbearing potential must be using and willing to continue to use medically acceptable contraception (i.e., hormonal oral contraceptive pills, patches, or vaginal rings, contraceptive implant or injection intrauterine contraceptive system [with or without hormone]) from Screening and for at least 90 days after the last study drug administration.
- Able to speak, read and understand English sufficiently to allow completion of all study assessments.
- Subjects must be able to provide meaningful written informed consent.
- Subjects must be willing and able to follow study instructions and be likely to complete all study requirements.
Exclusion Criteria:
- Substance or alcohol dependence (excluding nicotine and caffeine) within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition - Text Revision (DSM IV-TR), and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.
- History or presence of clinically significant abnormality as assessed by physical examination, medical history, electrocardiograms (ECGs), vital signs or laboratory values, which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results. Retesting may be permitted at the discretion of the investigator.
- History or presence of acute respiratory depression, chronic pulmonary disease, cor pulmonale, delirium tremens, central nervous system (CNS) depression, or increased cerebrospinal or intracranial pressure.
- Documented history of or currently active seizure disorder (excluding febrile seizures in childhood) or history of clinically significant head injury or syncope of unknown origin.
- History of gastrointestinal disturbance requiring frequent use of antacids.
- Subjects with a history of suicidal ideation within the past 6 months or a lifetime history of suicidal behavior, as assessed by the C SSRS (baseline version).
- Heavy smoker (>20 cigarettes per day) and/or is unable to abstain from smoking while housed at the clinical site.
- History of allergy or hypersensitivity to oxycodone, any other opioid or naloxone.
- Female subjects who are currently pregnant (have a positive pregnancy test) or lactating or who are planning to become pregnant within 30 days of last study drug administration.
- Positive for hepatitis B surface antigen (HBsAg), hepatitis C, human immunodeficiency virus (HIV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Evidence of clinically significant hepatic or renal impairment, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 × the upper limit of normal (ULN). Retesting may be permitted at the discretion of the investigator.
- Donation or loss of more than 500 mL whole blood within 30 days preceding entry into the Treatment Phase.
- Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
- Use of a prohibited medication or investigational product, as specified in Section 9.7.1.
- Is an employee of the sponsor or research site personnel directly affiliated with this study, or is an immediate family member of any of these persons, defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- Falls under any other condition, that, in the investigator's opinion, (i) puts the subject at increased risk, (ii) could confound the study results, (iii) may interfere significantly with the subject's participation in the study, or (iv) has the potential to limit the subject's ability to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PF614 100 mg capsule
Eligible subjects will be admitted to the clinical site on Day-1.
Subjects will receive PF614 100mg capsules in a randomized, double-blind, crossover manner.
|
PF614 100 mg capsules
Other Names:
|
Active Comparator: Oxycodone HCl tablets
Eligible subjects will be admitted to the clinical site on Day -1.
Subjects will receive crushed oxycodone HCl IR 40mg in a randomized, double-blind, crossover manner.
|
Oxycodone HCl IR 40mg
Other Names:
|
Placebo Comparator: Placebo powder in capsules
Eligible subjects will be admitted to the clinical site on Day-1.
Subjects will receive Placebo powder in a randomized, double-blind, crossover manner.
|
placebo powder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak Maximum Effect (Emax) for Drug Liking (At this Moment) Visual Analog Scale (VAS)
Time Frame: Up to 24 hour post-dose (up to Day 2)
|
Relative abuse potential of PF614 compared to Oxycodone and Placebo (I).
Emax for drug liking VAS will be reported.
Drug liking VAS is a bipolar scale designed to assess a participant's liking for a given study intervention at the time the question is being asked (that is, at this moment).
It is scored as an integer ranging from 0 (strong disliking) to 100 (strong liking)
|
Up to 24 hour post-dose (up to Day 2)
|
Take Drug again VAS (Emax)
Time Frame: 12 and 24 hours post-dose
|
Relative abuse potential of PF614 compared to Oxycodone and Placebo (II).
Emax for take drug again VAS will be reported.
Peak effect for take drug again based on bipolar VAS from 0 (definitely no) to 100 (definitely so).
|
12 and 24 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Plasma Concentration (Cmax)
Time Frame: Up to 24 hour post-dose (up to Day 2)
|
Compare the peak plasma concentration of oxycodone derived from PF614 and oxycodone derived from oxycodone IR tablets
|
Up to 24 hour post-dose (up to Day 2)
|
Time to Peak Plasma Concentration (Tmax)
Time Frame: Up to 24 hour post-dose (up to Day 2)
|
Compare the time to peak plasma concentration of oxycodone derived from PF614 and oxycodone derived from oxycodone IR tablets
|
Up to 24 hour post-dose (up to Day 2)
|
Area Under the Curve Plasma Concentration (AUC 0-24)
Time Frame: Up to 24 hour post-dose (up to Day 2)
|
Compare the 0-24 hr pharmacokinetic profile of oxycodone derived from PF614 and oxycodone derived from oxycodone IR tablets
|
Up to 24 hour post-dose (up to Day 2)
|
Adverse events (AEs)
Time Frame: Through study completion, an average of 7 weeks
|
Safety
|
Through study completion, an average of 7 weeks
|
Serious adverse events (SAEs)
Time Frame: Through study completion, an average of 7 weeks
|
Safety
|
Through study completion, an average of 7 weeks
|
AEs leading to discontinuation
Time Frame: Through study completion, an average of 7 weeks
|
Safety
|
Through study completion, an average of 7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Glen Apseloff, MD, FCP, Ohio Clinical Trials
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 10, 2022
Primary Completion (Actual)
August 31, 2022
Study Completion (Actual)
August 31, 2022
Study Registration Dates
First Submitted
May 22, 2022
First Submitted That Met QC Criteria
September 30, 2022
First Posted (Actual)
October 5, 2022
Study Record Updates
Last Update Posted (Actual)
December 27, 2022
Last Update Submitted That Met QC Criteria
December 23, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PF614-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recreational Drug Use
-
Ensysce BiosciencesDr. Vince Clinical ResearchCompletedRecreational Drug UseUnited States
-
Chinese University of Hong KongRecruiting
-
Eli Lilly and CompanyCompletedPrescription Drug Abuse (Not Dependent) | Recreational Drug UseUnited States
-
AstraZenecaCompletedRecreational CNS Depressant UseCanada
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy Recreational Drug UsersUnited States, Canada
-
Universiti Tunku Abdul RahmanCompleted
-
University of California, Los AngelesInstituto Nacional de Psiquiatría Dr. Ramón de la FuenteCompletedDrug Use | Harmful Use
-
University of Electronic Science and Technology...German Research Foundation; University Hospital, BonnCompletedRecreational Cannabis Use
-
University of California, Los AngelesCompleted
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarRecruiting
Clinical Trials on PF614
-
Ensysce BiosciencesPRA Health SciencesCompleted
-
Ensysce BiosciencesPRA Health SciencesCompleted
-
Ensysce BiosciencesDr. Vince Clinical ResearchCompletedRecreational Drug UseUnited States
-
Ensysce BiosciencesNational Institute on Drug Abuse (NIDA); Quotient SciencesCompletedPharmacokineticsUnited States